Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle Therapy

AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cells using Aegle’s proprietary and patented methods. The product is a composite of cell-derived nanoparticles that contain active biomolecules including proteins and nucleic acids with tissue regeneration, immunomodulation, and anti-inflammation properties.